Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The bladder cancer treatment market size was close to USD 4.03 billion in 2023, driven by the rising number of bladder cancer cases. The bladder cancer treatment market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032 to reach a value of USD 8.98 billion by 2032, driven by the rise in unhealthy lifestyles.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bladder cancer develops in the tissues of the urinary tract and is known as urological cancer. Cell division occurs uncontrollably in the epithelium and can spread into the bladder's muscular wall.
There is still no clear understanding of what causes bladder cancer. Depending on the type of cancerous cells, bladder cancer can be divided into three categories. The following types are:
Transitional Cell Carcinoma: This type of cancer is also called urothelial carcinoma. The disease occurs in bladder lining cells called urothelial cells. Among all bladder cancer types, this is the most common one.
Squamous Cell Carcinoma: A prolonged infection or stimulation leads to the development of this type of cancer in the bladder.
Adenocarcinoma: Bladder cancer occurs in glands located in the bladder lining. There are only a few cases of this type of bladder cancer.
There are several ways in which non-muscle invasive bladder cancer can be detected, including blood tests, urine cytology, cystoscopy, and computerised tomography.
Chemotherapy, immunotherapy, or surgery are the preferred treatment methods for bladder cancer.
On the other hand, prolonged exposure to radiation, tobacco consumption, chronic bladder infections, and smoking are among the risk factors. Any age group is susceptible to this condition. The condition is more common in older adults. Additionally, smoking is the leading cause of bladder cancer in the world.
According to the market research report, the bladder cancer treatment market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The bladder cancer treatment market growth is expected to be influenced by unhealthy lifestyles, such as bladder infections, genetic abnormalities, smoking, and chemical exposure. The bladder cancer treatment market is further expected to grow due to improvements in cancer treatment methods.
The market growth is predicted to be driven by an aging population as well. Increased treatment costs will further limit the growth of the market over the long term. Moreover, emerging markets offer opportunities for market growth. The bladder cancer therapy market, however, may be further hampered by post-treatment side effects.
The market in North America is largely driven by technological advances in medicine, especially cancer treatment. Moreover, bladder cancer treatment will benefit from increased healthcare spending in this region.
Research and development are expected to drive the bladder cancer treatment market growth in Asia-Pacific.
The availability of generic drugs and government awareness programs are also expected to generate significant growth in this region over the next few years.
Currently, researchers are testing immune checkpoint inhibitors for bladder cancer in the early stages and in combination with other treatments. The research includes:
Avelumab has been approved for the adjuvant treatment of bladder cancer that has not metastasized (locally advanced) or that has spread beyond the bladder (metastatic carcinoma).
Bladder cancer treatment depends on the type and stage of the disease. Research on new treatments and drugs is ongoing in addition to new combinations of existing treatments.
Drugs used in targeted therapy target specific cancer cells while causing little damage to normal cells. FDA approved erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial cancer in 2019.
A patient with an altered FGFR2 or FGFR3 gene may benefit from this medicine. It is estimated that FGFR gene mutations are responsible for 20% of bladder cancer cases.
Patients with advanced bladder cancer and mutations in the FGFR gene are undergoing a phase 3 trial that compares erdafitinib with standard chemotherapy and pembrolizumab.
The purpose of this study is to determine whether erdafitinib or an immune checkpoint inhibitor may be more beneficial in treating FGFR-mutant bladder cancer patients than chemotherapy.
In phase 3 trials, patients with muscle-invasive bladder cancer are receiving chemotherapy and radiation therapy with and without immune checkpoint inhibitor atezolizumab. Radiation therapy and chemotherapy combine to kill more cancer cells than chemotherapy alone. Patients with muscle-invasive bladder cancer may achieve better outcomes when atezolizumab (Tecentriq) is combined with radiation therapy and chemotherapy.
The monoclonal antibodies are proteins made in the laboratory and can bind to specific targets in the body, such as cancer cells. Monoclonal antibodies are chemically linked to drugs to form antibody-drug conjugates. It can kill cancer cells without harming normal cells.
Enfortumab vedotin-ejfv (Padcev) is also approved for treating advanced or metastatic bladder cancer. Positive results have been observed in patients who have previously been treated with chemotherapy and immune checkpoint inhibitors. A study is ongoing to determine whether this drug can be used together with immunotherapy and/or chemotherapy to treat bladder cancer early.
The report gives an in-depth analysis of the top players involved in the global bladder cancer treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Diagnosis Method |
|
Breakup by Treatment Method |
|
Breakup by Treatment Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Bladder Cancer Treatment Market Size
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032.
The market attained a value of USD 4.03 billion in 2023.
The market is expected to reach a value of USD 8.98 billion by 2032.
The factors stimulating the development of the market are bladder infections, genetic alteration, smoking, and chemical exposure, and a rise in R&D expenditure in biopharmaceutical companies.
Lack of awareness and rising treatment cost are the suspected reasons for hindering the growth of this market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
The top companies involved are AstraZeneca Plc., Bristol-Myers Squibb Co., Celgene Corporation, Pfizer Inc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., Merck & Co. Inc., Genetech Inc., Johnson & Johnson Services, Inc, Viventia Bio Inc., Spectrum Pharmaceuticals, Inc., Herantis Pharma Plc., Prometic Life Sciences Inc., and Taris Biomedical LLC.
The detection of non-muscle invasive bladder cancer can be done through blood tests, urine cytology, cystoscopy, or computerised tomography.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share